Publication Name	World Journal of Clinical Cases
Manuscript ID	71656
Country	China

Received	2021-09-17 14:15
Peer-Review Started	2021-09-17 14:16
To Make the First Decision
Return for Revision	2021-12-09 07:41
Revised	2021-12-22 03:56
Second Decision	2022-09-02 03:27
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2022-09-07 23:36
Articles in Press	2022-09-07 23:36
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-08-19 07:29
Typeset the Manuscript	2022-09-11 12:07
Publish the Manuscript Online	2022-09-29 09:17

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Case Report
Article Title	Vedolizumab in the treatment of immune checkpoint inhibitor-induced colitis: Two case reports
Manuscript Source	Unsolicited Manuscript
All Author List	Zhe Zhang and Chang-Qing Zheng
ORCID	Author(s) ORCID Number Zhe Zhang http://orcid.org/0000-0002-9178-6891 Chang-Qing Zheng http://orcid.org/0000-0003-4782-5715
Funding Agency and Grant Number
Corresponding Author	Chang-Qing Zheng, PhD, Doctor, Doctor, The Second Department of Gastroenterology, Shengjing Hospital of China Medical University, No. 39, Huaxiang Road, Tiexi District, Shenyang, Shenyang 110004, Liaoning Province, China. zhengchangqing88@163.com
Key Words	Immunotherapy; Colitis; Vedolizumab; Camrelizumab; Sintilimab; Case report
Core Tip	With its good efficacy, immunotherapy is increasingly being used in treating malignant tumors and attention shall be paid to the immune-related side effects caused by this therapy. This is a report on Sintilimab and Carrelizumab induced colitis which has rarely been reported in the past. Besides, a positive effect was achieved by adopting Vedolizumab combined with short-term corticosteroids therapy, which was different from the previous treatment.
Publish Date	2022-09-29 09:17
Citation	Zhang Z, Zheng CQ. Vedolizumab in the treatment of immune checkpoint inhibitor-induced colitis: Two case reports. World J Clin Cases 2022; 10(29): 10550-10558
URL	https://www.wjgnet.com/2307-8960/full/v10/i29/10550.htm
DOI	https://dx.doi.org/10.12998/wjcc.v10.i29.10550

Full Article (PDF)	WJCC-10-10550.pdf
Full Article (Word)	WJCC-10-10550.docx
Manuscript File	71656_Auto_Edited-YXX-Filipodia-LS.docx
Answering Reviewers	71656-Answering reviewers.pdf
Audio Core Tip	71656-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	71656-Conflict-of-interest statement.pdf
Copyright License Agreement	71656-Copyright license agreement.pdf
Signed Consent for Treatment Form(s) or Document(s)	71656-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	71656-Language certificate.pdf
Peer-review Report	71656-Peer-review(s).pdf
Scientific Misconduct Check	71656-Bing Xing YX-2.png
Scientific Editor Work List	71656-Scientific editor work list.pdf
CrossCheck Report	71656-CrossCheck report.pdf